AstraZeneca (AZN) Tops Q2 EPS by 93c, Beats on Revenue

AstraZeneca (NASDAQ: AZN) reported Q2 EPS of $1.72, $0.93 better than the analyst estimate of $0.79. Revenue for the quarter came in at $10.77 billion versus the consensus estimate of $10.51 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
• Definitive Healthcare names Clay Ritchey as new CEO